Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, open-label, non-randomised multi-center study of the histone deacetylase inhibitor belinostat in combination with carboplatin and paclitaxel (BelCaP) for the treatment of patients with urothelial carcinoma of the bladder (transitional cell carcinoma, or TCC).

Next Previous
Trial Profile

A Phase II, open-label, non-randomised multi-center study of the histone deacetylase inhibitor belinostat in combination with carboplatin and paclitaxel (BelCaP) for the treatment of patients with urothelial carcinoma of the bladder (transitional cell carcinoma, or TCC).

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Sep 2011

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Belinostat (Primary) ; Carboplatin (Primary) ; Paclitaxel (Primary)
  • Indications Bladder cancer
  • Focus Therapeutic Use

Most Recent Events

  • 14 Sep 2011 Status changed from not yet recruiting to completed, according to results presented at AACR-EORTC-NCI 2008.
  • 13 Sep 2011 Results reported in a TopoTarget media release, and will be presented at the 16th European Cancer Conference and the 36th Congress of the European Society for Medical Oncology.
  • 22 Oct 2008 Results were presented at AACR-EORTC-NCI 2008 Conference, according to a TopoTarget media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top